New approach could expand CAR T therapy from blood cancers to solid tumors

Researchers astatine the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute study that combining CAR T compartment immunotherapy with a targeted radiopharmaceutical importantly improved tumor regression successful preclinical models of neuroblastoma, a uncommon and assertive crab that usually forms successful nervus insubstantial extracurricular the encephalon and chiefly affects children. The findings were published successful Cell Reports Medicine.